Ocera Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2016-08-15: Study NCT03846843; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2014-01-07: Study NCT01966419; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2012-08: Study NCT01664637; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2011-09: Study NCT01452815; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2016-08-15 | NCT03846843 OCR002-SP103 - Oral Immediate Release Study | Lead sponsor | Phase 1 | Completed | Cirrhosis | 30 | 2017-12-31 |
| 2014-01-07 | NCT01966419 Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) | Lead sponsor | Phase 2 | Completed Results posted | Acute Episode of Overt Hepatic Encephalopathy; Hepatic Encephalopathy | 231 | 2016-12-29 |
| 2012-08 | NCT01664637 Diabetic Gastroparesis Efficacy/Safety Study of TZP-102 | Lead sponsor | Phase 2 | Terminated | Diabetic Gastroparesis | 120 | 2013-02 |
| 2011-09 | NCT01452815 Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis | Lead sponsor | Phase 2 | Completed | Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 201 | 2012-11 |
| 2011-03 | NCT01316484 Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms | Lead sponsor | Observational | Completed | Diabetes Mellitus; Gastroparesis | 40 | 2011-04 |
| 2011-02 | NCT01296620 Ulimorelin Study of Efficacy and Safety (ULISES 008) | Lead sponsor | Phase 3 | Completed | Gastrointestinal Dysmotility | 330 | 2012-03 |
| 2011-01 | NCT01285570 Ulimorelin Study of Efficacy and Safety (ULISES 007) | Lead sponsor | Phase 3 | Completed | Gastrointestinal Dysmotility | 332 | 2012-01 |
| 2009-04 | NCT00889486 Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus | Lead sponsor | Phase 2 | Completed | Gastroparesis; Diabetes Mellitus | 92 | 2010-04 |
| 2007-10 | NCT00612014 Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis | Lead sponsor | Phase 2 | Completed | Gastroparesis; Diabetes Mellitus | 78 | 2009-03 |
| 2007-07 | NCT00617552 Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery | Lead sponsor | Phase 2 | Completed | Postoperative Ileus | 267 | 2008-08 |
| 2006-08 | NCT00639808 Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis | Lead sponsor | Phase 1 | Completed | Gastroparesis; Diabetes Mellitus | 10 | 2008-03 |
| NCT01634230 Emergency Use of OCR-002 in Acute Liver Failure (ALF) | Lead sponsor | Expanded_access | No longer available | Acute Liver Failure |